Literature DB >> 21257005

Comparison of estimated glomerular filtration rates and albuminuria in predicting risk of coronary heart disease in a population with high prevalence of diabetes mellitus and renal disease.

Nawar M Shara1, Hong Wang, Eduardas Valaitis, Marieta Pehlivanova, Elizabeth A Carter, Helaine E Resnick, Wenyu Wang, Jason G Umans, Elisa T Lee, Barbara V Howard, Richard B Devereux, Peter W F Wilson.   

Abstract

Improved accuracy in predicting coronary heart disease (CHD) risk in patients with diabetes and kidney disease is needed. The addition of albuminuria to established methods of CHD risk calculation was reported in the Strong Heart Study (SHS) cohort. In this study, the addition of estimated glomerular filtration rate (eGFR) was evaluated using data from 4,549 American Indian SHS participants aged 45 to 74 years. After adjustment for Framingham CHD risk factors, hazard ratios for eGFR as a predictor of CHD were 1.69 (95% confidence interval 1.34 to 2.13) in women and 1.41 (95% confidence interval 0.94 to 2.13) in men. Models including albuminuria, eGFR, or both scored higher in discriminatory power than models using conventional risk factors alone in women; in men, the improvement was seen only for albuminuria and the combination of albuminuria and eGFR. Hosmer-Lemeshow assessments showed good calibration for the models using eGFR alone in both genders, followed by models including albuminuria alone in both genders. Adding eGFR improved the net reclassification improvement (NRI) in women (0.085, p = 0.0004) but not in men (0.010, p = 0.1967). NRI and integrated discrimination improvement (IDI) were improved in both genders using albuminuria and eGFR (NRI 0.135, p <0.0001, and IDI 0.027, p <0.0001 in women; NRI 0.035, p <0.0196, and IDI 0.008, p <0.0156 in men). Therefore, a risk calculator including albuminuria enhances CHD prediction compared to a calculator using only standard risk factors in men and women. Including eGFR alone improves risk prediction in women, but for men, it is preferable to include eGFR and albuminuria. In conclusion, this enhanced calculator should be useful in estimating CHD risk in populations with high prevalence of diabetes and renal disease.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21257005      PMCID: PMC3035999          DOI: 10.1016/j.amjcard.2010.09.036

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  29 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

3.  Combining GFR and albuminuria to classify CKD improves prediction of ESRD.

Authors:  Stein I Hallan; Eberhard Ritz; Stian Lydersen; Solfrid Romundstad; Kurt Kvenild; Stephan R Orth
Journal:  J Am Soc Nephrol       Date:  2009-04-08       Impact factor: 10.121

4.  Use and misuse of the receiver operating characteristic curve in risk prediction.

Authors:  Nancy R Cook
Journal:  Circulation       Date:  2007-02-20       Impact factor: 29.690

5.  Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population.

Authors:  Brad C Astor; Stein I Hallan; Edgar R Miller; Edwina Yeung; Josef Coresh
Journal:  Am J Epidemiol       Date:  2008-04-02       Impact factor: 4.897

6.  Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.

Authors:  Toshiharu Ninomiya; Vlado Perkovic; Bastiaan E de Galan; Sophia Zoungas; Avinesh Pillai; Meg Jardine; Anushka Patel; Alan Cass; Bruce Neal; Neil Poulter; Carl-Erik Mogensen; Mark Cooper; Michel Marre; Bryan Williams; Pavel Hamet; Giuseppe Mancia; Mark Woodward; Stephen Macmahon; John Chalmers
Journal:  J Am Soc Nephrol       Date:  2009-05-14       Impact factor: 10.121

7.  Definition of kidney dysfunction as a cardiovascular risk factor: use of urinary albumin excretion and estimated glomerular filtration rate.

Authors:  Massimo Cirillo; Maria Paola Lanti; Alessandro Menotti; Martino Laurenzi; Mario Mancini; Alberto Zanchetti; Natale G De Santo
Journal:  Arch Intern Med       Date:  2008-03-24

8.  Cardiovascular events and all-cause mortality by albuminuria and decreased glomerular filtration rate in patients with vascular disease.

Authors:  A L M Vlek; Y van der Graaf; W Spiering; A Algra; F L J Visseren
Journal:  J Intern Med       Date:  2008-06-03       Impact factor: 8.989

9.  Cross-classification of microalbuminuria and reduced glomerular filtration rate: associations between cardiovascular disease risk factors and clinical outcomes.

Authors:  Meredith C Foster; Shih-Jen Hwang; Martin G Larson; Nisha I Parikh; James B Meigs; Ramachandran S Vasan; Thomas J Wang; Daniel Levy; Caroline S Fox
Journal:  Arch Intern Med       Date:  2007-07-09

10.  Impacts of chronic kidney disease and albuminuria on associations between coronary heart disease and its traditional risk factors in type 2 diabetic patients - the Hong Kong diabetes registry.

Authors:  Xilin Yang; Ronald C Ma; Wing-Yee So; Gary T Ko; Alice P Kong; Christopher W Lam; Chun-Shun Ho; Clive S Cockram; Vivian C Wong; Peter C Tong; Juliana C Chan
Journal:  Cardiovasc Diabetol       Date:  2007-12-02       Impact factor: 9.951

View more
  7 in total

Review 1.  Coronary heart disease risk factors and outcomes in the twenty-first century: findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.

Authors:  Hemal Bhatt; Monika Safford; Stephen Glasser
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

2.  Estimated GFR and incident cardiovascular disease events in American Indians: the Strong Heart Study.

Authors:  Nawar M Shara; Hong Wang; Mihriye Mete; Yaman Rai Al-Balha; Nameer Azalddin; Elisa T Lee; Nora Franceschini; Stacey E Jolly; Barbara V Howard; Jason G Umans
Journal:  Am J Kidney Dis       Date:  2012-07-25       Impact factor: 8.860

3.  Association between urinary albumin excretion and coronary heart disease in black vs white adults.

Authors:  Orlando M Gutiérrez; Yulia A Khodneva; Paul Muntner; Dana V Rizk; William M McClellan; Mary Cushman; David G Warnock; Monika M Safford
Journal:  JAMA       Date:  2013-08-21       Impact factor: 56.272

4.  Replication of the effect of SLC2A9 genetic variation on serum uric acid levels in American Indians.

Authors:  V Saroja Voruganti; Nora Franceschini; Karin Haack; Sandra Laston; Jean W MacCluer; Jason G Umans; Anthony G Comuzzie; Kari E North; Shelley A Cole
Journal:  Eur J Hum Genet       Date:  2013-12-04       Impact factor: 4.246

5.  Prevalence, determinants and co-morbidities of chronic kidney disease among First Nations adults with diabetes: results from the CIRCLE study.

Authors:  Roland F Dyck; Mariam Naqshbandi Hayward; Stewart B Harris
Journal:  BMC Nephrol       Date:  2012-07-09       Impact factor: 2.388

6.  The association of genetic variants of type 2 diabetes with kidney function.

Authors:  Nora Franceschini; Nawar M Shara; Hong Wang; V Saroja Voruganti; Sandy Laston; Karin Haack; Elisa T Lee; Lyle G Best; Jean W Maccluer; Barbara J Cochran; Thomas D Dyer; Barbara V Howard; Shelley A Cole; Kari E North; Jason G Umans
Journal:  Kidney Int       Date:  2012-04-18       Impact factor: 10.612

7.  Chronic kidney disease in the type 2 diabetic patients: prevalence and associated variables in a random sample of 2642 patients of a Mediterranean area.

Authors:  Gabriel Coll-de-Tuero; Manel Mata-Cases; Antonio Rodriguez-Poncelas; Josep M A Pepió; Pilar Roura; Belen Benito; Josep Franch-Nadal; Marc Saez
Journal:  BMC Nephrol       Date:  2012-08-20       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.